Focus' Simplexa becomes first FDA-cleared H1N1 diagnostic
This article was originally published in Clinica
The US FDA has granted the first 510(k) clearance for an H1N1 test – Focus Diagnostics' Simplexa Influenza A H1N1 (2009) product. Previously, tests for the virus were only available through an emergency use authorisation (EUA), which allows the use of unapproved medical products during public health emergencies. The latest clearance means that the Simplexa test will still be available once the emergency expires. The test, which runs on the 3M Integrated Cycler, identifies H1N1 RNA using real-time reverse transcription PCR. It received an EUA in October 2009 (www.clinica.co.uk, 19 October 2009). Focus, a wholly-owned subsidiary of Quest Diagnostics, also CE marked it for sale in Europe in November 2009.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.